Overview

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Prospective, open label, non-randomized, phase I/IIb study of F16IL2 in combination with Nivolumab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Philogen S.p.A.
Treatments:
Nivolumab